In patients with a variety of advanced solid tumors AACR Symposium on from OncoMed Phase 1 dose-escalating monotherapy trial of OMP – 21M18 demonstrate positive evidence of disease control and tumor response as measured by RECIST criteria. Moreover show biomarker measurements that OMP 21M18 is a potent inhibitor of the Notch signaling pathway. Preliminary data from this ongoing study were presented at the 22 EORTC-NCI – AACR Symposium on ‘Molecular Targets and Cancer Therapeutics ‘November 16-19, presented in 2010 in Berlin, Germany.. OMP – 59R5 is part of OncoMed collaboration with GlaxoSmithKline and its further development in the clinic triggers a milestone payment from GSK for the companies.
In the United Statesry Panel voices concern over risks of HIV Vaccine Trials in adolescentsis an FDA advisory panel on Monday expressed concern about the possible risks of performing early HIV Vaccine Trials among teenagers in the U.S., reports Bloomberg. After the panel, although such studies in countries where HIV / AIDS prevalence is rapidly justified, the risks could not outweigh the benefits in the U.S.Spondylitis is painful, chronic inflammatory rheumatic disease with stiffen the vertrebral to column. Between 100,000 and 150,000 cases were have already been diagnosed in Germany, but more lenient forms of the disease not diagnose.